Lipid-Lowering Therapy: Statins as First-Line Treatment

Definition and pathophysiology

Lipid-lowering therapy is a central component of cardiovascular prevention, particularly in patients with established atherosclerotic cardiovascular disease (ASCVD), chronic coronary syndrome (CCS), peripheral artery disease (PAD), and acute coronary syndromes (ACS). Its principal therapeutic objective is reduction of low-density lipoprotein cholesterol (LDL-C), the primary lipid target in contemporary secondary prevention.

Statins inhibit hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme in cholesterol synthesis. Reduced hepatic cholesterol synthesis produces a compensatory increase in hepatic LDL-receptor expression, accelerating clearance of circulating LDL particles and lowering plasma LDL-C. Statin therapy also produces a modest, dose-dependent reduction in triglycerides.

The benefit of statins extends beyond angiographic reduction of coronary obstruction. Intensive lipid lowering improves endothelial function, lowers circulating high-sensitivity C-reactive protein, reduces thrombogenicity, and favourably modifies inflammatory and collagen-related components of atherosclerotic plaque. These effects help explain why reductions in cardiovascular events are substantially greater than the usually modest anatomical regression of coronary atherosclerosis.

The magnitude of LDL-C reduction varies according to the statin, dose, and individual response. In general, statins reduce LDL-C by approximately 30–55%; doubling the dose produces an additional reduction of approximately 6%.

Clinical indications and treatment goals

Established atherosclerotic cardiovascular disease

Patients with established ASCVD are at very high cardiovascular risk and require intensive LDL-C lowering. For patients with CCS, the recommended goal is:

• LDL-C <1.4 mmol/L (<55 mg/dL); and

• A reduction of at least 50% from baseline.

In patients who experience a recurrent atherothrombotic or cardiovascular event within 2 years while receiving maximally tolerated statin-based treatment, an LDL-C goal below 1.0 mmol/L (<40 mg/dL) may be considered.

Effective lipid lowering improves survival and reduces cardiovascular mortality in patients with coronary artery disease irrespective of the baseline cholesterol concentration. Intensive statin treatment is more effective than moderate-intensity treatment in reducing major cardiovascular events.

Acute coronary syndromes

The period immediately after ACS is particularly vulnerable, with recurrent cardiovascular events concentrated early after discharge. Consequently, lipid-lowering treatment should be initiated as soon as possible after admission rather than deferred until outpatient follow-up.

High-intensity statin treatment is recommended for all patients with ACS to reduce major adverse cardiovascular events. Therapy should preferably begin before planned percutaneous coronary intervention when feasible. Patients already taking low- or moderate-intensity statins should have treatment intensified.

The 2025 ACS guideline recommendations include:

• High-intensity statin therapy for all patients with ACS.

• Addition of a non-statin lipid-lowering agent in patients receiving maximally tolerated statin therapy whose LDL-C is ≥70 mg/dL (≥1.8 mmol/L).

• Reasonable addition of a non-statin agent when LDL-C is 55–69 mg/dL (≥1.4 to <1.8 mmol/L).

• Non-statin treatment for patients who are statin intolerant.

• Possible concurrent initiation of ezetimibe with maximally tolerated statin therapy during ACS hospitalization.

European recommendations support intensification of pre-existing lipid-lowering therapy during the index ACS admission. In treatment-naïve patients unlikely to achieve the LDL-C goal with statin therapy alone, initiation of high-intensity statin plus ezetimibe during hospitalization should be considered.

Chronic coronary syndrome

For all patients with CCS, a maximally tolerated high-intensity statin is recommended as first-line pharmacological treatment. Lifestyle measures, including exercise, dietary intervention, and weight control, should accompany pharmacological therapy.

High-intensity regimens specified in the source material are:

• Atorvastatin ≥40 mg once daily

• Rosuvastatin ≥20 mg once daily

These regimens reduce LDL-C by approximately 45–50% on average, although the response varies between individuals.

Peripheral artery disease

LDL-C reduction is also a key component of PAD management, including in patients without concomitant coronary or cerebrovascular disease. Statins reduce cardiovascular events and may improve limb outcomes. Reported benefits include reduced acute peripheral vascular events, greater pain-free walking distance with high-dose atorvastatin, and lower amputation risk in observational and meta-analytic data.

Clinical presentation and symptoms

Dyslipidaemia itself is generally clinically silent, and the source material does not describe a characteristic symptom complex attributable to elevated LDL-C. Its clinical significance is expressed through ASCVD manifestations, including coronary, cerebrovascular, and peripheral arterial events.

Symptoms and clinical syndromes therefore reflect the affected vascular territory rather than the lipid abnormality itself. In patients with established disease, lipid-lowering therapy is directed toward prevention of recurrent cardiovascular and limb events.

Evaluation and physical examination

The source material does not provide a detailed physical-examination framework for dyslipidaemia. Clinical assessment should nevertheless establish:

• Whether ASCVD is already present.

• Whether the patient has experienced ACS or another recent vascular event.

• Previous and current lipid-lowering treatment.

• The highest tolerated statin dose.

• Potential statin-associated muscle symptoms.

• Frailty, renal impairment, polypharmacy, and possible drug interactions, particularly in older patients.

• Pregnancy, planned pregnancy, or breastfeeding status.

• Cardiometabolic features relevant to secondary lipid targets, including obesity, metabolic syndrome, diabetes, and elevated triglycerides.

In older patients, treatment decisions should incorporate biological age, frailty, comorbidities, polypharmacy, possible drug interactions, expected lifetime benefit, and patient preferences. Renal impairment or interaction risk warrants cautious statin up-titration.

Diagnostics and laboratory assessment

Lipid profile

A fasting or nonfasting lipid panel should be obtained before starting statin treatment. LDL-C is the primary treatment target. Non-HDL cholesterol and apolipoprotein B are secondary targets, particularly in patients with cardiometabolic risk factors, triglycerides above 175 mg/dL, obesity, metabolic syndrome, diabetes, or relatively low LDL-C.

The percentage reduction in LDL-C from baseline should be assessed in addition to the achieved absolute LDL-C concentration.

After starting or intensifying treatment, lipid levels should be reassessed:

• Within 1–3 months according to the monitoring guidance; and

• At 4–6 weeks after treatment initiation or dose adjustment according to the ACS-specific recommendations.

The 4–6-week assessment is used to determine whether goals have been achieved and whether the regimen requires further adaptation.

Baseline safety testing

Before statin initiation, baseline testing should include:

• Alanine aminotransferase and other baseline transaminase assessment.

• Creatine kinase.

• Fasting or nonfasting lipid profile.

Glucose should be monitored in statin-treated individuals who have risk factors for diabetes.

Creatine kinase and muscle symptoms

Routine serial CK monitoring is not required in asymptomatic patients. CK measurement may be obtained when muscle symptoms occur, helping distinguish myalgia from myopathy. An isolated CK elevation without symptoms does not predict subsequent myopathy and does not necessarily require statin discontinuation.

Liver enzymes

Statins can cause mild, transient increases in alanine aminotransferase and aspartate aminotransferase. These elevations generally do not require treatment discontinuation.

Treatment and management

Lifestyle intervention

Lipid-lowering medication should be combined with:

• A healthy dietary pattern.

• Regular exercise.

• Weight control and attainment of an ideal body weight where appropriate.

• Smoking cessation.

• For hypertriglyceridaemia, weight loss, aerobic exercise, carbohydrate restriction, and limitation of alcohol intake.

Lifestyle measures are particularly important for patients with low HDL cholesterol, hypertriglyceridaemia, obesity, insulin resistance, and hypertension. However, HDL cholesterol is not established as a sole pharmacological treatment target for secondary prevention.

Statins as first-line therapy

Statins are the foundation of LDL-C reduction in both primary and secondary prevention. In patients with ASCVD or high cardiovascular risk, high-intensity treatment should be used at the highest tolerated dose capable of achieving the LDL-C goal and at least a 50% reduction from baseline.

Treatment should generally be continued indefinitely. In patients who tolerate therapy, dose reduction is not recommended merely because LDL-C has fallen substantially; the source material reports no adverse-effect signal among patients achieving very low LDL-C levels, including below 20 mg/dL in the cited long-term ACS experience.

Intensification with ezetimibe

Ezetimibe inhibits the intestinal cholesterol transporter NPC1L1, reducing intestinal cholesterol absorption by almost 60%. The usual dose is 10 mg once daily. As monotherapy, it lowers LDL-C by approximately 18%; its effect is additive to that of a statin, with an additional LDL-C reduction of approximately 20–25% reported when added to statin therapy.

Ezetimibe is recommended when the LDL-C goal is not achieved with the maximally tolerated statin dose. It may also be used as first-line therapy in patients who cannot tolerate any statin regimen.

In ACS, ezetimibe may be started early during the index admission, including within the first 10 days in the clinical evidence described. Early combination treatment is particularly relevant when baseline LDL-C makes achievement of the target with statin monotherapy unlikely.

When ezetimibe is combined with a statin, liver transaminase monitoring is recommended.

PCSK9 inhibition

Circulating PCSK9 promotes LDL-receptor degradation. PCSK9 monoclonal antibodies increase the availability of hepatic LDL receptors and lower LDL-C by approximately 60% when added to statin therapy. Alirocumab and evolocumab are administered subcutaneously every 2 or 4 weeks, depending on the preparation and regimen.

PCSK9 inhibitors are recommended for patients who remain above target despite maximally tolerated statin plus ezetimibe therapy. They may be particularly appropriate when a rapid and substantial additional reduction is required. In ACS, European guidance supports initiation during hospitalization in patients who were already receiving statin and ezetimibe but remained above goal.

PCSK9 inhibitors generally have a favourable safety profile. Injection-site reactions are the principal adverse effect reported as occurring more frequently than with placebo. They also modestly reduce lipoprotein(a), and clinical data describe benefits in patients with PAD, including reductions in major adverse limb events.

Bempedoic acid

Bempedoic acid inhibits ATP citrate lyase, reducing hepatic cholesterol synthesis through a pathway distinct from statins. It is activated by an enzyme not expressed in skeletal muscle, potentially accounting for its lower association with myalgia in comparison with statins.

The dose described is 180 mg once daily. LDL-C reductions are approximately:

• 18% when added to a statin.

• 23% as monotherapy.

• Approximately 36–38% when combined with ezetimibe.

Bempedoic acid is recommended for statin-intolerant patients who do not achieve their LDL-C goal with ezetimibe. It may also be considered in patients who remain above target despite maximally tolerated statin plus ezetimibe therapy.

Practical considerations include:

• It should not be combined with simvastatin doses above 20 mg.

• It may increase uric acid levels and precipitate gout.

• It may increase liver enzymes.

• Cholelithiasis has been reported.

• Unlike statins, it has not been associated with increased incident diabetes in the source material.

Inclisiran

Inclisiran is a small-interfering RNA therapy directed against PCSK9 messenger RNA in the liver. It is administered subcutaneously every 3–6 months, with the source material also describing a six-monthly schedule. It lowers LDL-C by approximately 50–60%, either with or without statin therapy.

Inclisiran appears well tolerated and effective for LDL-C reduction, but cardiovascular outcome trials are ongoing in the source material. Accordingly, the evidence base for event reduction is less mature than that for PCSK9 monoclonal antibodies.

Icosapent ethyl and triglycerides

In patients with ACS and triglycerides of 1.5–5.6 mmol/L (135–499 mg/dL) despite statin therapy, icosapent ethyl may be used at a dose of 2 g twice daily in combination with a statin.

The source material distinguishes purified eicosapentaenoic acid from nonprescription fish-oil preparations and from balanced preparations containing eicosapentaenoic acid and docosahexaenoic acid. Over-the-counter fish oils are not recommended for cardiovascular prevention.

For severe hypertriglyceridaemia, defined in the source material as triglycerides >500 mg/dL, treatment is important to prevent pancreatitis. Fibrates can lower triglycerides and may be useful in this setting, but fibrate treatment combined with statins has not demonstrated improved cardiovascular outcomes in the statin-era studies described.

Bile acid sequestrants

Bile acid sequestrants reduce LDL-C by binding bile acids in the intestine and increasing their faecal excretion. Available agents include cholestyramine, colestipol, and colesevelam.

They may be combined with statins or ezetimibe, but can increase triglycerides and should generally be avoided in patients with hypertriglyceridaemia. Gastrointestinal adverse effects include bloating and constipation. Because these agents are not systemically absorbed, they are considered particularly safe and are the preferred cholesterol-lowering drugs in children and in women who are pregnant, breastfeeding, or actively attempting conception.

Specialist therapies

For homozygous familial hypercholesterolaemia, the source material describes:

• Lomitapide, which reduces LDL-C by approximately 50%.

• Mipomersen, which reduces LDL-C by approximately 25%.

• Evinacumab, administered by intravenous infusion every 4 weeks, reducing LDL-C by approximately 50%.

Lomitapide and mipomersen can increase hepatic fat; lomitapide is also associated with gastrointestinal adverse effects, while mipomersen may cause skin reactions and influenza-like symptoms.

LDL apheresis may be considered in patients whose LDL-C remains unacceptably high despite maximally tolerated combination drug therapy, including a PCSK9 inhibitor. The source material specifies consideration in patients with coronary heart disease and LDL-C >200 mg/dL, those without coronary heart disease and LDL-C >300 mg/dL, and selected high-risk patients with LDL-C >160 mg/dL despite maximal therapy.

Drug safety and practical considerations

Statin-associated muscle symptoms

Myalgia is the most important commonly discussed adverse effect of statins and occurs in approximately 3–5% of patients in the source material. Severe myopathy with CK elevation and rhabdomyolysis are rare.

Risk is increased by:

• Older age.

• Frailty.

• Renal insufficiency.

• Concomitant drugs that interfere with statin metabolism, including erythromycin and related antibiotics, antifungal agents, immunosuppressive drugs, and fibric acid derivatives, particularly gemfibrozil.

When muscle symptoms occur, CK measurement may help define the syndrome. The source material does not provide a specific algorithm for rechallenge, switching, or dose interruption.

Hepatic considerations

Statins may cause mild or transient transaminase elevations. Baseline transaminase measurement is recommended, and liver tests should be interpreted in the clinical context rather than used as a reason for routine discontinuation in the setting of mild, transient abnormalities.

Diabetes risk

Statin therapy is associated with a slight excess of incident type 2 diabetes. This risk is outweighed by the cardiovascular benefit of statin treatment. Glucose monitoring is appropriate in patients with diabetes risk factors.

Pregnancy and breastfeeding

Statins should not be used when pregnancy is planned, during pregnancy, or during breastfeeding. Bile acid sequestrants are identified as the preferred lipid-lowering drugs in women who are pregnant, lactating, or actively trying to conceive.

Older adults

In patients aged ≥70 years, statins and other lipid-lowering therapies reduce major vascular events irrespective of age, although evidence is less direct for primary prevention. For primary prevention above this age, initiation may be considered in those at high or very high risk after considering frailty, comorbidities, polypharmacy, renal function, drug interactions, anticipated lifetime benefit, and patient preference.

Guideline-based treatment pathway

A practical secondary-prevention pathway is:

• Obtain baseline lipid profile, transaminases, and CK.

• Start or continue a maximally tolerated high-intensity statin.

• Aim for LDL-C <1.4 mmol/L (<55 mg/dL) and at least a 50% reduction from baseline.

• Recheck lipid levels after treatment initiation or intensification.

• Add ezetimibe if the LDL-C goal is not reached with statin therapy.

• Add a PCSK9 inhibitor if the goal remains unmet despite maximally tolerated statin plus ezetimibe.

• Consider bempedoic acid in appropriate statin-intolerant patients or as an additional option when targets remain unmet.

• Continue therapy lifelong and reassess adherence, tolerability, safety, and target attainment after each change.

The European CCS recommendations assign:

For ACS, the cited European recommendations state:

Prognosis and follow-up

Lower achieved LDL-C after ACS is consistently associated with lower cardiovascular event rates. Early and sustained attainment of guideline-recommended LDL-C goals is associated with the lowest observed cardiovascular risk after myocardial infarction in the data described.

A stepwise approach may delay achievement of the LDL-C goal for as long as 12 weeks after discharge. Because the early post-ACS period is the most vulnerable phase, treatment should be initiated promptly and intensified when necessary during the index hospitalization.

Lipid levels should be reassessed 4–6 weeks after each initiation, intensification, or dose adjustment to confirm response, assess adherence, identify safety concerns, and determine whether additional treatment is required. Broader monitoring after statin initiation includes repeat lipid testing within the first 1–3 months and glucose surveillance in patients at risk for diabetes.

Lipid-lowering treatment should be lifelong in patients with established ASCVD or ACS. Follow-up should focus on sustained LDL-C target attainment, persistence with therapy, adverse effects, drug interactions, renal and hepatic considerations, and the need for further combination treatment.